Business, energy, technology, markets and global industry news from Business News Today

Tenpoint Therapeutics

PharmaDeviceNews Tenpoint Therapeutics
Pharma & Biotech

Lupin’s VISUfarma gets exclusive European YUVEZZI rights as presbyopia eye drops become a competitive category

Lupin’s VISUfarma will handle YUVEZZI regulation and commercialization across the EU, UK and selected European markets, while Tenpoint receives an investment, milestones and tiered royalties.

Read More
Tenpoint Therapeutics is seeking MHRA authorisation for Yuvezzi, a once-daily dual-agent presbyopia eye drop for blurry close-up vision in adults. Representative image.
Pharma & Biotech

Tenpoint wants Yuvezzi to open a new UK presbyopia market, but another eye drop filed first

Tenpoint Therapeutics seeks UK authorisation for Yuvezzi, testing whether a dual-agent presbyopia eye drop can build a market beyond the United States.

Read More
Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety
Pharma & Biotech

Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety

YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.

Read More